Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stepwise evolution of therapy resistance in AML.
Gui P, Bivona TG. Gui P, et al. Among authors: bivona tg. Cancer Cell. 2021 Jul 12;39(7):904-906. doi: 10.1016/j.ccell.2021.06.004. Epub 2021 Jun 24. Cancer Cell. 2021. PMID: 34171262 Free article.
Mechanisms of resistance to EGFR targeted therapies.
Hrustanovic G, Lee BJ, Bivona TG. Hrustanovic G, et al. Among authors: bivona tg. Cancer Biol Ther. 2013 Apr;14(4):304-14. doi: 10.4161/cbt.23627. Epub 2013 Jan 28. Cancer Biol Ther. 2013. PMID: 23358468 Free PMC article. Review.
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J. Elkabets M, et al. Among authors: bivona tg. Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010. Cancer Cell. 2015. PMID: 25873175 Free PMC article.
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Shah KN, et al. Among authors: bivona tg. Nat Med. 2019 Jan;25(1):111-118. doi: 10.1038/s41591-018-0264-7. Epub 2018 Nov 26. Nat Med. 2019. PMID: 30478424 Free PMC article.
Polytherapy and Targeted Cancer Drug Resistance.
Chatterjee N, Bivona TG. Chatterjee N, et al. Among authors: bivona tg. Trends Cancer. 2019 Mar;5(3):170-182. doi: 10.1016/j.trecan.2019.02.003. Epub 2019 Feb 26. Trends Cancer. 2019. PMID: 30898264 Free PMC article. Review.
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. Chatterjee N, et al. Among authors: bivona tg. Cell Rep. 2019 Aug 27;28(9):2317-2330.e8. doi: 10.1016/j.celrep.2019.07.063. Cell Rep. 2019. PMID: 31461649 Free PMC article.
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Rotow JK, et al. Among authors: bivona tg. Clin Cancer Res. 2020 Jan 15;26(2):439-449. doi: 10.1158/1078-0432.CCR-19-1667. Epub 2019 Sep 23. Clin Cancer Res. 2020. PMID: 31548343 Free PMC article.
143 results